Bioguided study of the Antarctic alga Himantothallus grandifolius (A. Geep & E.S.Geep) indicates 13E-Docosenamide as potential antileishmanial agent

Leandro Costa Clementino1,2, Fabio Aurelio Esteves Torres1, Angela Maria Arenas Velasquez2, Leonardo Villela3, Toyota Fujii Mutue4, Pio Colepicolo3, Marcia A. S. Graminha2* 1São Paulo State University (UNESP), Chemistry Institute, Araraquara 14.800-900, Brazil. 2School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14.800-903, Brazil. 3Chemistry Institute, University of São Paulo (USP), São Paulo 05513-970, Brazil. 4Institute of Botany (IBt), São Paulo, 01061-970, Brazil.


INTRODUCTION
The food industries consume a wide range of algae, which are well known to have high contents of polysaccharides, fatty acids, sterols, fiber, minerals, vitamins, and a large number of antioxidants (Gambato et al., 2014;Pereira et al., 2012). Currently, the bioproducts isolated from the algae are promising and present great potential for the discovery of new therapeutic compounds. Although several natural products obtained from marine macroalgae have been identified and bioactively characterized, only a small number have been explored regarding their potential to produce antileishmanial agents (Cardozo et al., 2007;Torres et al., 2014). Himantothallus grandifolius (A and E Gepp) is a brown alga found in the Antarctic islands and sub-Antarctic regions; this macroalga is a member of the order Desmarestiales in the Phaeophyceae class and can reach a length of 17.5 m (Dieckmann et al., 1985;Drew and Hastings, 1992). This alga occurs in the Antarctic and sub-Antarctic regions, being found at a depth of 30-100 m in the Admiralty Bay, South Shetlands Islands (Dieckmann et al., 1985). Considering that this macroalga belongs to the same class as Sargassum, an edible alga, it is reasonable to suppose its potential commercial value (Gambato et al., 2014). Studies regarding the bioactivity potential of H. grandifolius have been poorly investigated and it is restricted to a single record describing an anticancer activity associated with phlorotannins ( Gambato et al., 2014;Iken et al., 2007). This work investigates the potential of H. grandifolius secondary metabolites against leishmaniasis. This parasitic disease endangers more than one billion people in endemic areas throughout the world and if left untreated it can lead to 20,000-30,000 deaths annually (Molyneux et al., 2016). Currently, there are few therapeutic options for the treatment of leishmaniasis including pentavalent antimony, amphotericin B, miltefosine, and paromomycin, which present several drawbacks such as high toxicity and low efficacy (Sundar and Chakravarty, 2015), which makes the discovery of new therapeutic alternatives urgent. Therefore, the aim of this study was to evaluate the antileishmanial activity of extracts and fractions of the Antarctic alga H. grandifolius against Leishmania amazonensis, the etiologic agent of cutaneous leishmaniasis, followed by UPLC-MS analyses revealing for the first time the antileishmanial properties of 13E-docosenamide.

Plant material
Samples of H. grandifolius were collected in Punta Plaza, King George Island, Antarctic Ocean, in January 2012 (62° 5′ × 58 ° 24′). The alga was identified by Dr. Toyota FujiiMutue in the laboratory of the Brazilian Antarctic base "Comandante Ferraz" (Gambato et al., 2014). The collected macroalgae were dried at room temperature, placed in a plastic bag, and kept at −80°C until use.
Mass detection was carried out for scanning the m/z between 50 and 1,100 in a positive mode with the following parameters: 4,500 V, endplate offset −500 V, nebulizer 2.0 Bar, dry heater 200ºC, and dry gas flow at a flow of 9 l minutes −1 .

Antipromastigote activity
To determine the half-maximal inhibitory concentration (IC 50 ), we carried out a colorimetric assay based on MTT as previously described (Velásquez et al., 2016), with modifications. Briefly, promastigotes were plated in 96-well plates at a density of 1 × 10 7 parasites ml −1 to a final volume of 100 µl and incubated at 28°C in the presence of increasing concentrations of H. grandifolius extracts (7.8-500 µg ml −1 ) or fractions (from 3.9 to 250 µg ml −1 ) dissolved in dimethyl sulfoxide (DMSO; the highest concentration was 1.4%, which was not hazardous to the parasites, as assessed previously) and incubated at 28°C for 72 hours. Then, 10 µl of an MTT-PMS solution (6 mM MTT; 0.7 mM PMS) was added to each well, followed by incubation for 75 minutes as described previously. For solubilization of the formazan crystals, they were added to a solution of 10% SDS/1M HCl, followed by another incubation for 30 minutes at room temperature and the absorbance was read in a microplate reader at 570 nm. Amphotericin B and untreated parasites were used as positive and negative controls, respectively. Additionally, a medium containing test extract/fraction/compound was also prepared in order to avoid any possible interference caused by the potential reducing capacity of the tested samples, which could increase the absorbance. The IC 50 promastigote was determined using nonlinear regression on Bioestat ® software. The assays were carried out in experimental triplicate and biological duplicates, and results were expressed as mean ± standard deviation.

Evaluation of cytotoxicity on peritoneal macrophages
The cytotoxicity of the H. grandifolius extracts, fractions, and 13E-docosenamide toward murine macrophages was determined in concordance with the protocol approved by the Institutional Ethics Committee, protocol CEUA/FCF/CAr no. 42/2016. In summary, cells (5 × 10 5 cells ml −1 ) were incubated in RPMI 1,640 medium, containing decreasing concentrations of extracts/fractions (according to that mentioned in the previous section) and 13E-docosenamide (1.5-100 µg ml −1 ), at a final volume of 100 µl per well, for 24 hours at 37°C in a 5% CO 2 -air. Their viability was measured by the MTT colorimetric assay with some modifications. Briefly, after incubation as described earlier, the supernatant was removed and 100 µl of ethanol and 100 µl of PBS : isopropanol (v/v) were added. The absorbance was read on a spectrophotometer at 570 nm. The cytotoxic concentration of compounds that resulted in 50% of cell growth inhibition (CC 50 ) was determined using nonlinear regression on Bioestat ® software.
The assays were carried out in experimental triplicate biological duplicate and results expressed as mean ± standard deviation.

Antiamastigote activity
To evaluate the antileishmanial activity of extracts/ fraction and 13E-docosenamide against L. amazonensis intracellular amastigotes, we used the following methodology (Velásquez et al., 2016). Murine peritoneal macrophages in RPMI 1,640 were seeded at a density of 5 × 10 5 cells ml −1 (300 µl final volume) containing coverslips of 13 mm in diameter arranged in a 24-well plate. After 6 hours of incubation at 37°C and 5% CO 2 -air mixture for macrophage adhesion, promastigote forms of L. amazonensis at the stationary growth phase (6-7 days) were added to the wells in a ratio of 10:1 (promastigotes:macrophages) and incubated for another 8 hours to allow parasite internalization. After incubation, the medium was replaced, noninternalized parasites were removed by PBS washing, and a new medium was added containing 250-15,62 µg ml −1 to extracts/fractions, 100-1,25 µmol l −1 to amphotericin B, and 33.7-2.1 µg ml −1 to 13E-docosenamide and plates were incubated for 24 hours at 37°C and 5% CO 2 -air mixture. Infected macrophages were used as a negative control and amphotericin B as a positive control.
After incubation, cells were fixed with methanol and Giemsa was stained. The concentration for 50% inhibition of amastigotes (IC 50 amastigote) was obtained by counting of 100 macrophages in two independent experiments. The values were obtained by nonlinear regression on Bioestat ® software, and results were expressed as mean ± standard deviation. Additionally, the ratio of antiamastigote activity to host cell toxicity, the selective index (SI = CC 50macrophages /IC 50 amastigote ) was determined. The infection index was determined according to Clementino et al. (2018) study. Statistical significant differences between treatments using 13E-docosenamide and control (untreated cells) were determined using "a one-way analysis" of variance, by Tukey's multiple comparison test (GraphPad Prism software). p-values < 0.05 (mean 95 % confidence interval) were considered statistically significant.

RESULTS AND DISCUSSION
Herein, we explored for the first time the antileishmanial activity of the Antarctic alga H. grandifolius. For this, hexane and ethanol extracts were obtained and analyzed regarding their potential antileishmanial and cytotoxic activities. Both ethanolic and hexanic extracts exhibited a mild anti-L. amazonensis promastigote effect (IC 50 = 112.0 and 144.5 μg ml −1 , resp.) and were at least two times more selective to the parasite rather than to the host cells (SI > 4.2 and 2.5, resp.); however, only the hexanic extract was able to maintain the leishmanicidal activity against amastigotes (IC 50 = 193.1 µg ml −1 ) ( Table 1). Following a bio-guided fractionation approach, chromatographic analysis of the bioactive hexane extract was carried out, indicating that most of the compounds are present in a retention time region between 10 and 22 minutes (Figure 1). Thus, the fractionation of this hexane extract produced 12 fractions (HGS) that were further investigated regarding the maintenance of their antileishmanial activity. The fractions HGS4-9 and HGS11-12 showed varied antiamastigote activity from 7 to 250 µg ml −1 (Table 1). Among them, the most potent fractions HGS11 (IC 50 = 12.3 µg ml −1 ; SI > 9.3) and HGS12 (IC 50 = 7.8 µg ml −1 ; SI > 5.1) showed a similar range of activity when compared to amphotericin B (IC 50 = 5.3 µg ml −1 ; SI = 1.3) and so the chemical nature was putatively determined.
Since both HGS11 and HGS12 were collected in a short time frame of only one millisecond apart, it is not possible to rule out that HGS11 might contain part of 13E-docosenamide from HGS12, which would suggest the presence of this fatty acid in both subfractions. Besides, the intensity of 13E-docosenamide in HGS12 is nearly 10 times higher than HGS11, which might explain why HGS12 (IC 50 = 7.8 µg ml −1 ) is almost twice as active as HGS11 (IC 50 = 12.3 µg ml −1 ). Moreover, among the other compounds present in HGS12, the 3-ethyl-5-methoxy-N-{4-[4-(2-methylphenyl)-1piperidinyl]cyclohexyl}-1H-indole-2-carboxamide (Table 2S)   previously characterized as an anti-Plasmodium falciparum agent (Gamo et al., 2010), suggesting that H. grandifolius is a rich source of other natural products that can be explored for the development of new drugs to treat other infectious diseases.
Besides the large use of marine macroalgae as food and source of polyunsaturated fatty acids (omega 3 and 6) and steroids Santos et al., 2017), they are also well known as an important source of bioactive natural products, which have been explored for the discovery of new therapeutic agents Pacheco et al., 2018) or as starting material for the synthesis of known drugs (Cardozo et al., 2007;Gressler et al., 2011). Indeed, these organisms feature several new chemicals, showing biological effects such as antitumor, anti-inflammatory, analgesic, immunomodulatory, antiallergic, antiviral, and antiparasitic activities (Blunt et al., 2010;Mayer et al., 2013;Newman and Cragg, 2016). Flavonoids, chalcones, lignans, coumarins, iridoids, monoterpenes, saponins, curcumin, quinoline alkaloids, and polyketides are among the natural products from marine sources that exhibit antileishmanial properties (Falkenberg et al., 2019).
The chemical profile showed that peak 15 from HGS11 (Table 1S) matches the triterpeneroxburghiadiol B previously characterized as anti-inflammatory, antiviral, and anticancer agents (Janaki et al., 1999). Indeed, other triterpenes isolated from the terrestrial plant Maytenus ilicifolia, maytenin and pristimerin, also show antileishmanial activity (Dos Santos et al., 2013). In addition, this same peak may also contain the marine metabolite 25-hydroxysarcosterol, a sterol with unknown bioactivity, which was first isolated from the coral species Sarcophyton glaucum and Sinularia mayi (Kobayashi, 1994;Wang et al., 2013). Another interesting data refers to the peaks 16 from HSG11 ( Figure 1S) and 22 from HSG12 ( Figure  2S), both corresponding to the fatty acid 13E-docosenamide (Figure 3), already described as a chemical constituent of the dinoflagellate microalgae Symbiodinium spp. and previously explored regarding its potential antibacterial and antifungal properties (dos Reis et al., 2019;Garg et al., 2018;Parkinson and Baums, 2014;Pradheesh, 2017;Zhang et al., 2018).
The great advantage of seaweeds in drug discovery is not only their enormous diversity of secondary metabolites presenting different bioactivities (Falkenberg et al., 2019), but also the possibility of their large-scale cultivation (de Oliveira Fernandes et al., 2017;Huang and Rorrer 2002;Rorrer et al., 1995) and utilizing green extraction technologies to obtain the desired secondary metabolites, as well as other bioproducts with biotechnological potential (Górka and Wieczorek 2017;Ospina et al., 2017;Prieto-Sandoval et al., 2018).

CONCLUSION
This study reveals that the antileishmanial potential of Antarctic alga H. grandifolius and the effect of the compound 13E-docosenamide against L. amazonensis amastigotes, the most important form involved in disease development, indicate its great potential for the next steps on drug discovery in the treatment of cutaneous leishmaniasis.